This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Neuroendocrine tumors	CD56	<p>Patient sample and mouse studies suggest CD56⁺ NK cells could help treat neuroblastoma. <i>In vitro</i>, peripheral blood mononuclear cells from healthy donors were selected for cell surface CD56 expression, mixed 1:1 with CD56⁻ cells and then activated using a combination of IL-12, IL-15 and a CD3 antibody. In xenograft mice with neuroblastoma cell lines, the activated mixture decreased tumor growth compared with nonactivated NK cells or no treatment. Next steps include a clinical trial of the cells in patients with neuroblastoma.</p> <p>SciBX 6(11); doi:10.1038/scibx.2013.263 Published online March 21, 2013</p>	Patent and licensing status undisclosed	<p>Rujkijyanont, P. <i>et al. Cancer Res.</i>; published online Feb. 25, 2013; doi:10.1158/0008-5472.CAN-12-3322 Contact: Wing Leung, St. Jude Children's Research Hospital, Memphis Tenn. e-mail: wing.leung@stjude.org</p>